Renal outcomes in patients with type 1 diabetes and macroalbuminuria

Journal of the American Society of Nephrology

Volumn 25, Issue 10, 2014, Pages 2342-2350

  De Boer, Ian H ^a   Afkarian, Maryam ^a   Rue, Tessa C ^b   Cleary, Patricia A ^c   Lachin, John M ^c   Molitch, Mark E ^d   Steffes, Michael W ^e   Sun, Wanjie ^c   Zinman, Bernard ^f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C;

ADULT; ALBUMIN EXCRETION RATE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY INJURY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; ALBUMINURIA; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE COURSE; MIDDLE AGED; NORTH AMERICA; PATHOPHYSIOLOGY;

ADULT; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORTH AMERICA; RISK FACTORS;

EID: 84922251376     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013091004     Document Type: Article

References (36)

1. Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32[Suppl 2]: 64-78, 1983
2. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in type I diabetes. Am J Med 78: 785-794, 1985
3. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25: 496-501, 1983
4. Molitch ME, Steffes M, SunW, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J; Epidemiology of Diabetes Interventions and Complications Study Group: Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33: 1536-1543, 2010
5. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B;DCCT/EDICResearchGroup: Intensive diabetes therapy and glomerular fi ltration rate in type 1 diabetes. N Engl J Med 365: 2366-2376, 2011
6. Costacou T, Ellis D, Fried L, Orchard TJ: Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: A cohort study. AmJ Kidney Dis 50: 721-732, 2007
7. Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS: The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 82: 589-597, 2012
8. Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH; FinnDiane Study Group: Competing-risk analysis of ESRD and death among patients with type 1 diabetes andmacroalbuminuria. J Am Soc Nephrol 22: 537-544, 2011
9. Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS: Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 22: 545-553, 2011
10. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
11. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47: 1703-1720, 1995
12. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ; Collaborative Study Group: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. AmJ Kidney Dis 34: 809-817, 1999
13. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60: 277-283, 2001
14. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 36: 383-388, 1976
15. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1: 1175-1179, 1983
16. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001
17. Mulec H, Blohmé G,Grände B, Björck S: The effect ofmetabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 13: 651-655, 1998
18. Breyer JA, Bain RP, Evans JK,NahmanNS Jr., Lewis EJ, CooperM,McGill J, Berl T; The Collaborative Study Group: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50: 1651-1658, 1996
19. American Diabetes Association: Standards of medical care in diabetes - 2014. Diabetes Care 37[Suppl 1]: S14-S80, 2014
20. National Kidney Foundation: KODQI clinical practive guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60: 850-886, 2012
21. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606, 2000
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
23. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patientswith nephropathy due to type 2 diabetes. NEngl J Med 345: 851-860, 2001
24. Yamamoto T, Nakagawa T, Suzuki H,Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A: Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 18: 1558-1565, 2007
25. Dolan V, Hensey C, Brady HR: Diabetic nephropathy: Renal development gone awry? Pediatr Nephrol 18: 75-84, 2003
26. Zhang Y, Zhang Q: Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 383: 1-3, 2009
27. Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS, Yaghobian Azari D, Jun M, Poulter N, Hamet P, Williams B, Neal B, Mancia G, Cooper M, Pollock CA: Circulating bone morphogenetic protein-7 and transforming growth factor-b1 are better predictors of renal end points in patients with type 2 diabetesmellitus. Kidney Int 83: 278-284, 2013
28. Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 21: 212-222, 2010
29. Kawakami T, Ren S, Duffield JS:Wnt signalling in kidney diseases: Dual roles in renal injury and repair. J Pathol 229: 221-231, 2013
30. Bonegio R, Susztak K: Notch signaling in diabetic nephropathy. Exp Cell Res 318: 986-992, 2012
31. Austin SM, Lieberman JS, Newton LD, Mejia M, Peters WA, Myers BD: Slope of serial glomerular fi ltration rate and the progression of diabetic glomerular disease. J Am Soc Nephrol 3: 1358-1370, 1993
32. Kussman MJ, Goldstein H, Gleason RE: The clinical course of diabetic nephropathy. JAMA 236: 1861-1863, 1976
33. Watkins PJ, Blainey JD, Brewer DB, Fitzgerald MG, Malins JM, O'Sullivan DJ, Pinto JA: The natural history of diabetic renal disease. A follow-up study of a series of renal biopsies. Q J Med 41: 437-456, 1972
34. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
35. de Boer IH, KestenbaumB, Rue TC, SteffesMW,Cleary PA,MolitchME, Lachin JM,Weiss NS, Brunzell JD; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group: Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med 168: 1867-1873, 2008
36. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, England J, Bucksa J, Nowicki M: Hemoglobin A1c measurements over nearly two decades: Sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem 51: 753-758, 2005